NADAC acquisition cost data for ANORO ELLIPTA 62.5-25 MCG INH. This is a brand-name medication — generic alternatives may be available at lower prices.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 00173086910 | $7.16 | 2022-01-01 | Rx |
| 00173086906 | $7.37 | 2022-01-01 | Rx |
| 00173086906 | $7.37 | 2022-01-01 | Rx |
| 00173086910 | $7.16 | 2022-01-01 | Rx |
| 00173086910 | $7.16 | 2022-01-01 | Rx |
| 00173086906 | $7.37 | 2022-01-01 | Rx |
| 00173086910 | $7.16 | 2022-01-01 | Rx |
| 00173086906 | $7.37 | 2022-01-01 | Rx |
| 00173086910 | $7.16 | 2022-01-01 | Rx |
| 00173086906 | $7.37 | 2022-01-01 | Rx |
Generic: Umeclidinium Brm/Vilanterol Tr | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $825.9M | 1,599,052 | 360,112 | $6.93 |
| 2020 | $1.0B | 1,830,197 | 375,201 | $7.15 |
| 2021 | $912.4M | 1,593,170 | 338,712 | $7.46 |
| 2022 | $866.8M | 1,439,975 | 297,142 | $7.78 |
| 2023 | $873.0M | 1,390,293 | 294,512 | $8.07 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| New York | $67.2M | 106,083 | 22,778 |
| Pennsylvania | $64.1M | 110,077 | 22,491 |
| Florida | $57.5M | 84,611 | 20,243 |
| California | $57.0M | 91,090 | 20,309 |
| Texas | $42.0M | 64,789 | 14,835 |
| Ohio | $37.4M | 60,236 | 13,047 |
| Illinois | $34.4M | 54,564 | 11,700 |
| North Carolina | $30.9M | 52,091 | 10,942 |
| Indiana | $28.8M | 44,444 | 9,949 |
| Michigan | $27.7M | 42,362 | 10,158 |
| Massachusetts | $26.0M | 42,337 | 8,760 |
| New Jersey | $25.8M | 40,116 | 8,768 |
| Georgia | $25.4M | 40,180 | 8,741 |
| Tennessee | $24.4M | 37,603 | 8,638 |
| Missouri | $24.3M | 39,746 | 8,023 |
| Virginia | $18.5M | 29,129 | 6,312 |
| Wisconsin | $17.8M | 29,015 | 5,827 |
| Connecticut | $17.1M | 25,296 | 5,570 |
| Kentucky | $16.9M | 27,033 | 6,051 |
| Alabama | $16.0M | 26,071 | 5,765 |
| Arizona | $15.1M | 22,007 | 5,266 |
| South Carolina | $14.9M | 23,725 | 5,466 |
| Maryland | $14.7M | 21,446 | 5,101 |
| Iowa | $12.8M | 22,227 | 4,253 |
| Washington | $12.5M | 19,981 | 4,303 |
| Minnesota | $11.4M | 18,518 | 3,900 |
| Louisiana | $11.2M | 19,387 | 4,162 |
| Colorado | $10.5M | 15,610 | 3,504 |
| Arkansas | $10.1M | 16,911 | 3,439 |
| Oklahoma | $10.0M | 16,374 | 3,493 |
| Oregon | $10.0M | 15,951 | 3,507 |
| Maine | $7.9M | 11,367 | 2,541 |
| Kansas | $7.8M | 13,031 | 2,509 |
| Mississippi | $7.5M | 12,391 | 2,687 |
| Nebraska | $6.5M | 11,372 | 2,162 |
| West Virginia | $5.1M | 8,309 | 1,930 |
| Puerto Rico | $5.1M | 10,608 | 2,019 |
| Nevada | $4.8M | 7,170 | 1,748 |
| Delaware | $4.3M | 5,845 | 1,446 |
| New Hampshire | $4.2M | 6,483 | 1,379 |
| Rhode Island | $3.5M | 6,546 | 1,325 |
| Idaho | $3.2M | 5,290 | 1,146 |
| Utah | $3.0M | 4,689 | 1,058 |
| Vermont | $2.7M | 4,092 | 902 |
| South Dakota | $2.7M | 4,634 | 873 |
| New Mexico | $2.5M | 4,070 | 933 |
| Montana | $2.3M | 3,833 | 775 |
| North Dakota | $2.2M | 3,625 | 743 |
| Hawaii | $1.6M | 2,382 | 584 |
| District of Columbia | $1.2M | 1,803 | 454 |
| Alaska | $1.1M | 1,449 | 379 |
| Wyoming | $979.4K | 1,543 | 350 |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.